Singapore biotech startup Automera raises $16m

Series A round co-led by U.S. company and Temasek-backed ClavystBio

20230928 DSA Automera

Automera, launched on Wednesday, is a biotechnology company focusing on development of autophagy-targeting chimera small molecules. (Screenshot from Automera's website)

KEERTAN AYAMANY, DealStreetAsia

KUALA LUMPUR -- Singapore-based Biotech startup Automera has received $16 million in Series A funding co-led by U.S.-based Accelerator Life Science Partners (ALSP) and Temasek-backed ClavystBio.

EDBI and Xora Innovation also joined the round with other undisclosed investors.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.